CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Collaboration revenue	$ 1,955	$ 41,196	$ 1,595
Royalty income	6,608	3,101	5,923
Research grants	0	0	275
Other revenues	113	80	69
Total revenues	8,676	44,377	7,862
Expenses:
Research and development	28,196	28,592	34,582
General and administrative	18,184	15,489	15,541
Intangible impairment charge	0	2,676	919
Change in contingent consideration liability	1,600	1,500	(200)
Total expenses	47,980	48,257	50,842
Other operating Income	0	7,250	0
Operating (loss) income	(39,304)	3,370	(42,980)
Other income:
Interest income	52	51	46
Total other income	52	51	46
(Loss) income before income tax benefit	(39,252)	3,421	(42,934)
Income tax benefit	133	989	362
Net (loss) income	(39,119)	4,410	(42,572)
Net loss attributable to noncontrolling interests	(7)	0	0
Net (loss) income attributable to Progenics	$ (39,112)	$ 4,410	$ (42,572)
Net (loss) income per share attributable to Progenics - basic	$ (0.56)	$ 0.06	$ (0.76)
Weighted-average shares - basic	69,716	68,185	55,798
Net (loss) income per share attributable to Progenics - diluted	$ (0.56)	$ 0.06	$ (0.76)
Weighted-average shares - diluted	69,716	68,243	55,798